HMPC: overview of assessment work - priority list
Submitted by Anonymous (not verified) on 30 January 2026 - 11:28
HMPC: overview of assessment work - priority list
Committee on Herbal Medicinal Products (HMPC): Work Plan 2026
Submitted by Anonymous (not verified) on 30 January 2026 - 11:25
Committee on Herbal Medicinal Products (HMPC): Work Plan 2026
Meeting on the impact of chemical and environmental policies on the healthcare sector and availability of medicines, European Medicines Agency, Amsterdam, the Netherlands, 19 December 2025
Submitted by Anonymous (not verified) on 30 January 2026 - 11:10
Meeting on the impact of chemical and environmental policies on the healthcare sector and availability of medicines, European Medicines Agency, Amsterdam, the Netherlands, 19 December 2025
First treatment for rare thymidine kinase 2 deficiency
Submitted by Anonymous (not verified) on 30 January 2026 - 11:01
First treatment for rare thymidine kinase 2 deficiency
New medicine to treat chronic graft-versus-host disease
Submitted by Anonymous (not verified) on 30 January 2026 - 11:01
New medicine to treat chronic graft-versus-host disease
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 26-29 January 2026
Submitted by Anonymous (not verified) on 30 January 2026 - 11:00
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 26-29 January 2026
Human medicines European public assessment report (EPAR): Fylrevy, estetrol, Status: Opinion
Submitted by Anonymous (not verified) on 30 January 2026 - 11:00
Human medicines European public assessment report (EPAR): Fylrevy, estetrol, Status: Opinion
Human medicines European public assessment report (EPAR): Ilumira, lutetium (177Lu) chloride, Status: Opinion
Submitted by Anonymous (not verified) on 30 January 2026 - 11:00
Human medicines European public assessment report (EPAR): Ilumira, lutetium (177Lu) chloride, Status: Opinion
Human medicines European public assessment report (EPAR): Kayshild, semaglutide, Status: Opinion
Submitted by Anonymous (not verified) on 30 January 2026 - 11:00
Human medicines European public assessment report (EPAR): Kayshild, semaglutide, Status: Opinion
Human medicines European public assessment report (EPAR): Kygevvi, doxecitine,doxribtimine, Status: Opinion
Submitted by Anonymous (not verified) on 30 January 2026 - 11:00
Human medicines European public assessment report (EPAR): Kygevvi, doxecitine,doxribtimine, Status: Opinion